APM
BMY.RT

Avidity Partners Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Avidity Partners Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,684,932
Closed -$51M – 120
2020
Q3 		$51M Buy
22,684,932
+16,897,991
+292% +$48.3M 2.37% 13
2020
Q2 		$20.7M Buy
+5,786,941
New +$20.9M 1.33% 27

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Avidity Partners Management's BMY.RT Position: Q4 2020 in Review

Avidity Partners Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 22,684,932 shares — an estimated $51M sold.

Avidity Partners Management first reported a position in BMY.RT in Q2 2020 and held it in 2 quarters. The position peaked at $51M in Q3 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Avidity Partners Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Avidity Partners Management sold 22,684,932 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $51M.
  • Avidity Partners Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 2 quarters.
  • Avidity Partners Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $51M in Q3 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.